Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab

C. Toth, L. Martin, W. Morrish, S. Coutts, Ian F Parney

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background - Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids. Aim - To describe a case of steroid-refractory neurosarcoidosis with a marked clinical and radiological response to infliximab. Methods - We describe the case of a young female patient with biopsy-proven neurosarcoidosis leading to gait failure. She described significant corticosteroid-related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication. Results - Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement. Conclusion - Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
JournalActa Neurologica Scandinavica
Volume116
Issue number4
DOIs
StatePublished - Oct 2007
Externally publishedYes

Fingerprint

Adrenal Cortex Hormones
Therapeutics
Gait
Infliximab
Neurosarcoidosis
Steroids
Magnetic Resonance Imaging
Pharmacology
Biopsy
Drug Therapy

Keywords

  • Corticosteroids
  • Infliximab
  • Neurosarcoidosis
  • Sarcoidosis
  • Tumor necrosis factor α inhibitors

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. / Toth, C.; Martin, L.; Morrish, W.; Coutts, S.; Parney, Ian F.

In: Acta Neurologica Scandinavica, Vol. 116, No. 4, 10.2007, p. 259-262.

Research output: Contribution to journalArticle

Toth, C. ; Martin, L. ; Morrish, W. ; Coutts, S. ; Parney, Ian F. / Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab. In: Acta Neurologica Scandinavica. 2007 ; Vol. 116, No. 4. pp. 259-262.
@article{0b16ca800dc74235b04f3ca15cb623ce,
title = "Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab",
abstract = "Background - Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids. Aim - To describe a case of steroid-refractory neurosarcoidosis with a marked clinical and radiological response to infliximab. Methods - We describe the case of a young female patient with biopsy-proven neurosarcoidosis leading to gait failure. She described significant corticosteroid-related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication. Results - Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement. Conclusion - Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.",
keywords = "Corticosteroids, Infliximab, Neurosarcoidosis, Sarcoidosis, Tumor necrosis factor α inhibitors",
author = "C. Toth and L. Martin and W. Morrish and S. Coutts and Parney, {Ian F}",
year = "2007",
month = "10",
doi = "10.1111/j.1600-0404.2007.00870.x",
language = "English (US)",
volume = "116",
pages = "259--262",
journal = "Acta Neurologica Scandinavica",
issn = "0001-6314",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Dramatic MRI improvement with refractory neurosarcoidosis treated with infliximab

AU - Toth, C.

AU - Martin, L.

AU - Morrish, W.

AU - Coutts, S.

AU - Parney, Ian F

PY - 2007/10

Y1 - 2007/10

N2 - Background - Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids. Aim - To describe a case of steroid-refractory neurosarcoidosis with a marked clinical and radiological response to infliximab. Methods - We describe the case of a young female patient with biopsy-proven neurosarcoidosis leading to gait failure. She described significant corticosteroid-related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication. Results - Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement. Conclusion - Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.

AB - Background - Neurosarcoidosis is often a devastating, refractory condition without definite pharmacotherapies beyond corticosteroids. Aim - To describe a case of steroid-refractory neurosarcoidosis with a marked clinical and radiological response to infliximab. Methods - We describe the case of a young female patient with biopsy-proven neurosarcoidosis leading to gait failure. She described significant corticosteroid-related side effects without clinical response to the therapy. Infliximab therapy was considered as a possible rescue medication. Results - Within months of starting intravenous infliximab therapy, she regained her ability to walk and magnetic resonance imaging identified significant improvements over a sustained course of infliximab therapy, including loss of enhancing nodules and loss of meningeal enhancement. Conclusion - Mounting evidence suggests that infliximab is a valuable pharmacological agent in the management of patients with refractory and disabling neurosarcoidosis. Controlled studies of infliximab in this condition are needed.

KW - Corticosteroids

KW - Infliximab

KW - Neurosarcoidosis

KW - Sarcoidosis

KW - Tumor necrosis factor α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=34548483687&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548483687&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0404.2007.00870.x

DO - 10.1111/j.1600-0404.2007.00870.x

M3 - Article

VL - 116

SP - 259

EP - 262

JO - Acta Neurologica Scandinavica

JF - Acta Neurologica Scandinavica

SN - 0001-6314

IS - 4

ER -